ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Cerchione, C. [1 ]
Alfinito, F. [2 ]
Soriente, I. [3 ]
D'Arco, A. M. [3 ]
Danise, P. [3 ]
Cerciello, G. [3 ]
Musuraca, G. [1 ]
Lucchesi, A. [1 ]
Di Battista, V. [1 ]
Cangini, D. [1 ]
Giannini, M. B. [1 ]
Ronconi, S. [1 ]
Ceccolini, M. [1 ]
Pane, F. [2 ]
Martinelli, G. [1 ]
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, Italy
[2] AOU Federico II, Hematol, Naples, Italy
[3] Osped Pagani, Hematol, Pagani, Italy
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P001
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [41] MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS : EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE
    Cerchione, C.
    Vitagliano, O.
    Simeone, L.
    Pareto, A. E.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Alfinito, F.
    Pane, F.
    HAEMATOLOGICA, 2015, 100 : 482 - 482
  • [42] Drug utilization and cost considerations of erythropoiesis-stimulating agents in patients with myelodysplastic syndromes
    Lalibert, Francois
    McKenzie, Scott R.
    Bookhart, Brahim K.
    Duh, Mei S.
    Lefebvre, Patrick
    BLOOD, 2007, 110 (11) : 225B - 225B
  • [43] Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes
    Oarbeascoa, Gillen
    Redondo, Sara
    Jose Moran-Jimenez, Maria
    Domingo, Amalia
    Munoz-Linares, Cristina
    Isabel Moreno-Carralero, Maria
    Maria Bellon, Jose
    del Campo Rincon, Juan Francisco
    Luis Diez-Martin, Jose
    Font, Patricia
    BLOOD, 2018, 132
  • [44] Current treatment strategies in low-risk myelodysplastic syndromes
    Giagounidis, Aristoteles A. N.
    Germing, Ulrich
    Aul, Carlo
    CANCER TREATMENT REVIEWS, 2007, 33 : S19 - S24
  • [45] BURDEN OF DISEASE IN LOW-RISK MYELODYSPLASTIC SYNDROMES IN SPAIN
    Valcarcel, D.
    Montoro, M. J.
    Tormo, M.
    Bargay, J.
    Moreno, E.
    Aceituno, S.
    Bellmunt, A.
    Soler, M.
    Rafel, M.
    Villarrubia, R.
    VALUE IN HEALTH, 2022, 25 (12) : S155 - S156
  • [46] Supportive Care for Patients With Myelodysplastic Syndromes
    Stempel, Jessica M.
    Podoltsev, Nikolai A.
    Dosani, Talib
    CANCER JOURNAL, 2023, 29 (03): : 168 - 178
  • [47] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Erica Tsang
    Heather A. Leitch
    Annals of Hematology, 2016, 95 : 73 - 78
  • [48] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang, Erica
    Leitch, Heather A.
    ANNALS OF HEMATOLOGY, 2016, 95 (01) : 73 - 78
  • [49] Erythropoiesis stimulating agents (ESAs) for congestive heart failure: The red and the black
    Roberto Robles, Nicolas
    Francisco Macias, Juan
    Herrera, Julio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (02) : 193 - 196
  • [50] Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS)
    Veys, N.
    Van Biesen, W.
    Lameire, N.
    ACTA CLINICA BELGICA, 2007, 62 (06) : 396 - 407
12345